PIK3CA and cancer: For instance, a combination of glutaminase (GLS) inhibitor CB839 and 5-FU chemotherapy drug increases the anti-cancer effect on the xenograft growth of PIK3CA-mutant CRC cells without significant dose-limiting toxicity (Zhao Y. et al., 2020).